Received Jul 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | X449Y | — |
administration of a second dose of Boostrix, 1 week apart from 1st dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 12-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number X449Y, expiry date 20-OCT-2026) for prophylaxis. Concomitant products included Diphtheria vaccine toxoid, Pertussis vaccine acellular 3-component, Tetanus vaccine toxoid (Boostrix). On 21-JUL-2025, the patient received the 2nd dose of Boostrix. On 21-JUL-2025, an unknown time after receiving Boostrix, the patient experienced extra dose administered (Verbatim: administration of a second dose of Boostrix, 1 week apart from 1st dose). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 22-JUL-2025 The reporter reported that there was administration of a second dose of Boostrix, 1 week apart to a patient, which led to extra dose administered. She called to know how proceed and if there were some safety comments to be shared with the parents of patient. The Vaccine Administration Facility was the same as Primary Reporter.